The Depo-Provera multidistrict litigation has reached a size that should command the attention of more than litigation teams. As of July 1, 2026, the Judicial Panel on Multidistrict Litigation reported 5,830 pending actions in MDL No. 3140. That represented an...
A major mass tort verdict can transform the market almost overnight. Within hours, the result may appear in legal publications, social media posts, newsletters, vendor presentations, and advertising conversations. Competing firms may announce plans to expand their...
The Federal Dupixent Litigation Has Entered a New Phase On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation (JPML) centralized federal lawsuits alleging that Dupixent (dupilumab) caused, accelerated, or delayed the diagnosis of cutaneous T-cell...
Mass tort developments move quickly. A new multidistrict litigation filing, centralization order, expert ruling, bellwether result, regulatory communication, or reported settlement development can create immediate pressure inside a plaintiff firm: Should we launch a...
Social media addiction litigation creates an unusual tension for plaintiff law firms: some of the companies named as defendants also operate the advertising and content-distribution platforms firms use to reach potential claimants. Meta, TikTok,...
GLP-1 medications have become one of the most visible drug categories in the country, and the public conversation around side effects has grown just as quickly. Patients are posting about nausea, vomiting, constipation, gallbladder issues, delayed gastric emptying,...